Psychiatr. pro Praxi, 2008; 9(6): 292-295 [Prakt. lékáren. 2008; 4(5): 206-210]

INVEGA - paliperidon ER tablety s prodlouženým uvolňováním

MUDr. Ivan Tůma CSc
Psychiatrická klinika LF UK a FN Hradec Králové

Paliperidon tablety s pozvolným uvolňováním jsou nové antipsychotikum registrované v indikaci léčby schizofrenie. Paliperidon 9 – hydroxyrisperidon je aktivním metabolitem antipsychotika druhé generace risperidonu. Tableta připravená v OROS (Osmotic controlled-Release Oral delivery System) technologii zajišťuje pozvolné uvolňování aktivní látky v průběhu pasáže tablety gastrointestinálním traktem. Tableta proto nesmí být půlena nebo rozkousnuta. OROS forma zajišťuje relativně stabilní plazmatickou hladinu léku. Dlouhý poločas vylučování umožňuje jednoduché dávkování jednou denně v ranní dávce. Klinický efekt srovnatelný s mateřskou molekulou risperidonu, relativně příznivější profil nežádoucích účinků a jednoduché dávkování zvyšují šanci na zlepšení adherence psychotických pacientů k léčbě.

Keywords: Klíčová slova: antipsychotika, paliperidon, schizofrenie.

Published: December 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tůma I. INVEGA - paliperidon ER tablety s prodlouženým uvolňováním. Psychiatr. praxi. 2008;9(6):292-295.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Conley R., Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Opin 2006; 22: 1879-1892. Go to original source... Go to PubMed...
    2. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy abd safety abd aerly responze of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Res 2007; 93: 117-130. Go to original source... Go to PubMed...
    3. Invega (paliperidone) extended-release tablets: prescribing information. Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2006-2008 (http://www.invega.com/invega/shared/pi/invega.pdf#zoom=100).
    4. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: A 6 weeks placebo-controlled trial. Schizophrenia Res 2007; 90: 147-161. Go to original source... Go to PubMed...
    5. Karlsson P, Dencker E, Nyberg S. Pharmacokinetics and dopamine D(2) and serotonin 5-HT(2A) receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005; 15 (Suppl. 3): 386. Go to original source...
    6. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005 May; 162(5): 1010-1012. Go to original source... Go to PubMed...
    7. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27(1): 6-14. Go to original source... Go to PubMed...
    8. Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti WP, Palumbo JM. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007; 22(5): 299-308. Go to original source... Go to PubMed...
    9. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007; 62: 1363-1370. Go to original source... Go to PubMed...
    10. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies. J Clin Psychiatry 2008 May 6: e1-e13. Go to original source... Go to PubMed...
    11. Mohr P. Paliperidon s prodlouženým uvolňováním. Remedia 2007; 17: 586-591.
    12. Švestka J, Doležal T. Paliperidon, antipsychotikum 2. generace: účinnost, snášenlivost a lékové interakce. Psychiatrie 2007; 11: 226-234.
    13. Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry. 2008; 16(1): 31-43. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.